Format

Send to

Choose Destination
Pharmacol Res. 2019 Dec;150:104497. doi: 10.1016/j.phrs.2019.104497. Epub 2019 Oct 17.

Role of biological agents in treatment of rheumatoid arthritis.

Author information

1
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, OX3 7LD, UK.
2
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, OX3 7LD, UK. Electronic address: peter.taylor@kennedy.ox.ac.uk.

Abstract

Advances in understanding of the pathophysiology of rheumatoid arthritis with concurrent advances in protein engineering led to the development of biological disease-modifying antirheumatic drugs which have dramatically revolutionized the treatment of this condition. This review article focuses on the role of biological agents currently employed in the treatment of rheumatoid arthritis, as well as novel biological agents in development.

KEYWORDS:

Biological disease-modifying antirheumatic drugs; Review; Rheumatoid arthritis

PMID:
31629903
DOI:
10.1016/j.phrs.2019.104497

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center